45 related articles for article (PubMed ID: 20682979)
1. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
2. XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
Huang MY; Huang YJ; Cheng TL; Jhang WY; Ke CC; Chen YT; Kuo SH; Lin IL; Huang YH; Chuang CH
Cells; 2023 May; 12(11):. PubMed ID: 37296596
[TBL] [Abstract][Full Text] [Related]
3. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
[TBL] [Abstract][Full Text] [Related]
4. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
[TBL] [Abstract][Full Text] [Related]
5. Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan/hyaluronic acid/protamine polyplexes containing CRISPR-Cas9.
Shirani-Bidabadi S; Mirian M; Varshosaz J; Tavazohi N; Sadeghi HMM; Shariati L
Biochim Biophys Acta Gen Subj; 2023 Aug; 1867(8):130385. PubMed ID: 37230419
[TBL] [Abstract][Full Text] [Related]
6. Association between ERCC1 Gene Polymorphism (rs11615) and Colorectal Cancer Susceptibility: A Meta-Analysis of Medical Image Fusion and Safety Applications.
Liu M; Qiu Z; Yang Q
Comput Math Methods Med; 2022; 2022():9988513. PubMed ID: 36277013
[TBL] [Abstract][Full Text] [Related]
7. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells.
Tanaka S; Hosokawa M; Miyamoto T; Nakagawa A; Haruna M; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Rep; 2021 Jul; 26():100996. PubMed ID: 33898768
[TBL] [Abstract][Full Text] [Related]
8. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
Rao D; Mallick AB; Augustine T; Daroqui C; Jiffry J; Merla A; Chaudhary I; Seetharam R; Sood A; Gajavelli S; Aparo S; Rajdev L; Kaubisch A; Chuy J; Negassa A; Mariadason JM; Maitra R; Goel S
Oncotarget; 2019 Sep; 10(53):5510-5522. PubMed ID: 31565185
[TBL] [Abstract][Full Text] [Related]
9. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
[TBL] [Abstract][Full Text] [Related]
10. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.
Orlandi A; Di Salvatore M; Bagalà C; Basso M; Strippoli A; Plastino F; Calegari MA; Cassano A; Astone A; Barone C
J Cancer; 2015; 6(1):70-81. PubMed ID: 25553091
[TBL] [Abstract][Full Text] [Related]
12. Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells.
de Oliveira LZ; Farias IL; Rigo ML; Glanzner WG; Gonçalves PB; Cadoná FC; Cruz IB; Farias JG; Duarte MM; Franco L; Bertol G; Colpo E; Brites PC; Rocha JB; Leal DB
Evid Based Complement Alternat Med; 2014; 2014():274786. PubMed ID: 25505920
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.
Filipovic L; Arandelovic S; Gligorijevic N; Krivokuca A; Jankovic R; Srdic-Rajic T; Rakic G; Tesic Z; Radulovic S
Radiol Oncol; 2013; 47(4):346-57. PubMed ID: 24294179
[TBL] [Abstract][Full Text] [Related]
14. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.
Muniz VP; Askeland RW; Zhang X; Reed SM; Tompkins VS; Hagen J; McDowell BD; Button A; Smith BJ; Weydert JA; Mezhir JJ; Quelle DE
Genes Cancer; 2013 Jul; 4(7-8):273-84. PubMed ID: 24167655
[TBL] [Abstract][Full Text] [Related]
15. Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.
Bavykin AS; Korotaeva AA; Poyarkov SV; Syrtsev AV; Tjulandin SA; Karpukhin AV
Onco Targets Ther; 2013; 6():1333-40. PubMed ID: 24098083
[TBL] [Abstract][Full Text] [Related]
16. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
Flamant L; Roegiers E; Pierre M; Hayez A; Sterpin C; De Backer O; Arnould T; Poumay Y; Michiels C
BMC Cancer; 2012 Sep; 12():391. PubMed ID: 22954140
[TBL] [Abstract][Full Text] [Related]
17. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
Gordon MA; Zhang W; Yang D; Iqbal S; El-Khouiery A; Nagashima F; Lurje G; Labonte M; Wilson P; Sherrod A; Ladner RD; Lenz HJ
Pharmacogenomics; 2011 Jan; 12(1):27-39. PubMed ID: 21174620
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
